AbCellera Biologics Inc. Overview
Pro stress-test →AbCellera is a clinical-stage biotech company that transitioned in 2025 with a fully built platform and a growing pipeline of multiple potential first-in-class programs. The company's lead program, ABCL635, is a potential first-in-class antibody targeting the neurokinin 3 receptor for treating moderate-to-severe vasomotor symptoms associated with menopause.
Strategic Profile
Pro stress-test →With approximately $655 million in available liquidity as of Q1 2026, AbCellera maintains a strong cash position to execute its strategy. The company has reached a cumulative total of 104 partner-initiated program starts with downstream partners and has 19 molecules that have reached the clinic. In June 2026, AbCellera entered a collaboration with Jazz Pharmaceuticals for T-cell engaging multispecific antibodies, receiving $56 million upfront plus potential milestone payments up to $792 million per program.
Competitive Landscape
Pro stress-test →AbCellera competes in the therapeutic antibody discovery and development space alongside established players like Regeneron, Amgen, and Genmab. The company differentiates through its proprietary antibody discovery platform, partnership model generating upfront and milestone revenue from discovery programs, and focus on first-in-class mechanisms. The competitive advantage lies in platform efficiency attracting major pharma collaborations while maintaining a lean clinical pipeline.
Industry Context
AbCellera Biologics Inc. operates in Therapeutic antibody discovery and development.
Key facts
Founded: 2012 · Headquarters: Vancouver, British Columbia · Revenue: $75.1M (FY 2025) · Market cap: $1.6B